UNITED STATES

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~ 14November 20, 2017

HEALTH ADVANCE INC.

(Exact name of registrant as specified in its charter)

Wyoming		333-177122		46-0525223
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

~~3651~~685 ~~Lindell~~Citadel ~~Rd.~~Drive East - Suite ~~D155~~290 ~~Las~~Colorado ~~Vegas~~Springs, NVCO ~~89103~~80909 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: 719-466-6699 N/A (Former name or former address, if changed since last report)

Registrant’s telephone number, including area code: 702-943-0309

N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] ~~Soliciting~~Pre-commencement ~~material~~communications pursuant to Rule ~~14a~~14d-122(b) under the Exchange Act (17 CFR 240.~~14a~~14d-122(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~[ ]~~Item ~~Pre-commencement~~5.02, ~~communications~~Departure ~~pursuant~~of toDirectors ~~Rule~~or ~~14d-2(b)~~Principal ~~under~~Officers; ~~the~~Election ~~Exchange~~of ~~Act~~Directors; ~~(17~~Appointment ~~CFR~~of ~~240.14d-2(b))~~Principal Officers;

~~[ ]~~Health ~~Pre-commencement~~Advance ~~communications~~Inc. ~~pursuant~~('HADV' toor ~~Rule~~the ~~13e-4(c~~'the Company'), ~~under~~announces that Mr. Jordan Starkman has resigned from the ~~Exchange~~Board ~~Act~~of ~~(17~~Directors ~~CFR~~of ~~240.13e-4~~HADV (cthe 'Board')), as well as from the position of Board Executive, President, and Director with his resignation taking effect from November 1, 2017. Mr. Starkman has been a Board Executive, Director, and President since the Company's inception. Health Advance Inc. would like to thank Mr. Starkman for his time and dedication and we wish him well in his future business ventures.

~~This~~The ~~Current~~Company ~~Report~~appoints onVice ~~Form~~Chairman ~~8-K~~and ~~includes~~Director, ~~certain~~Gregory ~~statements~~Shusterman ~~that~~as ~~are “forward-looking statements” within~~ the ~~meaning~~Chairman of the ~~Private~~Board ~~Securities~~and ~~Litigation~~Executive ~~Reform~~Director, ~~Act~~Christian ofDiesveld ~~1995.~~as ~~Any statement in this report that is not~~ a ~~statement~~voting ofDirector ~~historical fact may be deemed to be a forward-looking statement. We often use these types~~ of ~~statements when discussing our plans and strategies, our anticipation of revenues from designated markets and statements regarding~~ the ~~development of our businesses~~Board, ~~the markets for our services~~ and products, our anticipated capital expenditures, operations, support systems, changes in regulatory requirements and other statements contained in this report regarding matters that are not historical factsDr. ~~When~~Muhammad ~~used~~Mukhtar inas ~~this report,~~ the ~~words~~Special ~~“expect,”~~Advisor ~~“anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate” and other similar expressions are generally intended~~ to ~~identify~~the ~~forward-looking~~Chairman ~~statements. Because these forward-looking statements involve risks~~ and ~~uncertainties,~~shall ~~actual results may differ materially from those expressed or implied by these forward-looking statements. There can~~ be ~~no assurance that: (i) we have correctly measured or identified all of~~ the ~~factors~~appointed ~~affecting us or the extent of their likely impact;~~ (iiInterim) ~~the~~Chief ~~publicly~~Executive ~~available~~Officer ~~information~~and ~~with~~a respect to these factors on which our analysis is based is complete or accurate; (iii) our analysis is correct; or (iv) our strategy, which is based in part on this analysis, will be successful. We do not assume any obligation to update or revise any forwardnon-~~looking~~voting ~~statements,~~Director ~~whether as a result~~ of ~~new~~the ~~information, future events or otherwise~~Board.

~~Item~~Thereby, Mr. Shusterman, Mr. Diesveld, and Dr. Mukhtar’s appointment are effective from November 1, 2017.02 ~~Termination~~HADV intends to simplify its overall management structure and is in the process of ahiring ~~Material~~and ~~Definitive~~electing ~~Agreement~~new executive management for the new fiscal year.

~~On June 14, 2017, Health Advance Inc~~Mr. ~~(the~~Shusterman ~~“Company”)~~is ~~sent written notice to Micro Medtech, Ltd.,~~ a ~~foreign~~Canadian ~~limited~~citizen ~~liability~~who ~~company~~has ~~held~~worked previously in ~~Federated~~various ~~States~~senior ofleadership ~~Micronesia,~~positions ~~existing~~for as a ~~foreign~~number ~~corporation in the State~~ of ~~Colorado,~~companies ~~United~~in ~~States (“MMT”) to terminate~~ the ~~license~~healthcare ~~agreement~~industry ~~dated February 28, 2017~~ and ~~entered~~has ~~into~~work onexperience ~~March~~as ~~5, 2017 (~~the ~~“License~~Vice ~~Agreement”)~~Chairman ~~to acquire exclusive licensing rights in North America to cebidiofen~~ and ~~polyoxyfen,~~‘Acting ~~two~~Chairman’ ~~patent-pending, product formulations~~ for ~~pharmaceutical~~the ~~foods~~Company ~~made~~since ~~from~~being ~~ibuprofen~~elected ~~and~~in ~~botanical~~April ~~extract blends containing cannabidiol, mitragyna speciose, and kava. Pursuant to the terms~~ of ~~the~~this ~~License Agreement, the License Agreement may be cancelled by providing ninety (90) days written notice to MMT~~year. ~~Accordingly, the License Agreement shall terminate on September 12, 2017.~~

~~Item 4~~Mr.02 ~~Non-Reliance~~Diesveld is a Canadian citizen and UK resident who has worked previously in various senior leadership positions for a number of ~~Previously~~companies, ~~Issued~~including, ~~Financial~~but ~~Statements~~not orlimited to, Hantian Labs Limited, a ~~Related~~recent ~~Audit~~acquisition ~~Report~~of orthe ~~Completed~~Company, ~~Interim~~where ~~Review~~Mr. Diesveld was recently named UK CEO of the Year – Small Enterprise in the Health and Wellness sector

OnDr. ~~June~~Mukhtar ~~14,~~has ~~2017,~~served as a ~~Quarterly~~professor ~~Report~~at onthe ~~Form~~American ~~10-Q~~University ~~for~~of ~~the~~Ras ~~period~~Al ~~ended~~Khaimah ~~January 31~~(AURAK), ~~2017~~United ~~(the~~Arab ~~“June~~Emirates. 14Before ~~10-Q”)~~his ~~was~~arrival ~~filed~~at onAURAK, ~~behalf~~he ofserved ~~the~~as ~~Company~~Vice ~~with~~Chancellor/Professor ~~the signature~~ of ~~Gregory~~three ~~Shusterman,~~Universities anin ~~individual~~Pakistan ~~claiming~~concomitantly to– bea ~~Chairman~~unique ofhonor ~~the~~for ~~Board~~any ofacademic ~~Directors of the Company~~leader. ~~Mr.~~ ~~Shusterman~~Through ishis ~~not~~wise anacademic ~~officer,~~leadership ~~director,~~and orinnovative ~~employee of the Company~~governance, ~~does~~he ~~not~~converted ~~have~~a ~~access~~regional tohigher ~~the~~education ~~Company’s~~institution ~~internal~~in ~~financial~~Pakistan ~~statements, and had no authority or authorization~~ to ~~file~~one of the ~~June 14 10~~top-Qranked onin ~~behalf of~~ the ~~Company~~country. ~~Further,~~ ~~Mr.~~Mukhtar ~~Shusterman~~received ~~did~~his ~~not~~Master ~~consult~~and ~~with~~MPhil orin ~~receive approval or authorization from~~ the ~~Company’s~~field ~~independent auditor to file the June 14 10-Q. That same day, the Company was made aware~~ of ~~this~~Biochemistry ~~improper~~from ~~filing~~Pakistan and ishis ~~notifying~~Ph.D. ~~shareholders~~in ~~and~~biosciences ~~the~~from ~~public to not rely on~~ the ~~June~~Drexel 14University ~~10-Q,~~of ~~which has incorrect information~~Philadelphia, ~~financial statements and exhibits. The Company is still compiling the financial statements for the quarter ended January 31~~USA, ~~2017~~ and ~~intends~~also tocompleted ~~file~~ a ~~Quarterly~~Graduate ~~Report~~Certificate onin ~~Form~~Research ~~10-Q~~Management ~~for~~from ~~the~~Thomas ~~period~~Jefferson ~~ended~~University ~~January~~in 31Philadelphia, ~~2017~~USA. ~~once~~He ~~the~~served ~~financial~~in ~~statements~~various ~~have~~academic/administrative ~~been~~positions ~~completed~~in ~~and~~ the ~~Company’s~~USA ~~independent~~on ~~auditor~~an ~~has~~outstanding ~~had~~scientist a(O-1) ~~chance to review them~~visa.

~~Item~~Mukhtar 9is an avid researcher also.01 ~~Financial~~His ~~Statement~~laboratory developed an in-vitro model of the human blood-brain barrier to study viral neuropathogenesis. Dr. Mukhtar as Principal or Co-Investigator has received several awards from organizations including American Diabetes Association, American Society for Microbiology, Diabetes Trust Foundation, US National Institutes of Health, Pfizer Pharmaceuticals (NYSE: PFE), and ~~Exhibits~~the Higher Education Commission of Pakistan. Human blood-brain barrier model developed in his laboratory is extensively used to understand ferrying of viruses into the brain and finding cures for neurological ailments.

~~(d)~~Dr. ~~Exhibits~~Mukhtar holds specialized Certificates in Public Health and Bioinformatics. Committed to the role of technology in biomedical research, he serves as managing editor of Frontiers in Bioscience and is on the editorial board of several research journals. He feels pride in mentoring researchers, scientists, teachers and administrators and committed professionals aspiring to excel in their practical life. He has several research publications, including peer- reviewed research, review articles, invited articles, book chapters, commissioned articles and critiques to his credit. A book describing accomplishments of Dr. Mukhtar’s educational leadership has been published in Urdu language entitled “Hayat Zauq e Safar Kay Siwa Kuch Aur Naheen” and it’s English Version “The Making of a Best National University” is in progress.

Exhibit No.	Description
99.1	Termination Letter from the Company to Micro Medtech, Ltd. dated June 14, 2017

Reference is made to this disclosure set under Item 6 of this SEC Form 8-K and SEC Form 10-Q/A for the transition period from February 1, 2017 through April 30, 2017, which include Item 6 - Exhibits [99.2 and 99.3] of this Report, which disclosure is incorporated herein by reference, in addition to being pursuant to the results of Civil Case No. 17CV132-S, U.S. Court of Wyoming District on September 22, 2017.

~~SIGNATURES~~ Item 9.01 Financial Statements and Exhibits.

~~Pursuant~~Exhibit to99.1: ~~the~~Letter ~~requirements~~ of ~~the~~Resignation ~~Securities~~Undersigned ~~Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf~~ by ~~the~~Jordan ~~undersigned hereunto duly authorized.~~Starkman

		Health Advance Inc.
Date: June 14, 2017		/s/ Jordan Starkman
		Jordan Starkman
		President, Chief Executive Officer, Chief Financial Officer, Chairman of the Board of Directors

This Current Report on Form 8-K includes certain statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement in this report that is not a statement of historical fact may be deemed to be a forward-looking statement. We often use these types of statements when discussing our plans and strategies, our anticipation of revenues from designated markets and statements regarding the development of our businesses, the markets for our services and products, our anticipated capital expenditures, operations, support systems, changes in regulatory requirements and other statements contained in this report regarding matters that are not historical facts. When used in this report, the words “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate” and other similar expressions are generally intended to identify forward-looking statements. Because these forward-looking statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements. There can be no assurance that: (i) we have correctly measured or identified all of the factors affecting us or the extent of their likely impact; (ii) the publicly available information with respect to these factors on which our analysis is based iscomplete or accurate; (iii) our analysis is correct; or (iv) our strategy, which is based in part on this analysis, will be successful. We do not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Health Advance Inc.

Date: November 20, 2017	X	Gregory Shusterman
		Gregory Shusterman
		Executive Director;
		Chairman of the Board of Directors

Filing Compare · HEALTH ADVANCE INC.